As of October 28, 2026, CRISPR Therapeutics AG has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 19, 2026 (Form 8-K, October 19, 2026).
Sell to companies like CRISPR Therapeutics AG? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CRISPR Therapeutics AG reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-19. Every row below is cited to the filing it comes from, and this page adds each new change as CRISPR Therapeutics AG files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-19 | Reported | not named in the filing | 8-K, 2026-10-19 |
Selling to them or working with them? See who runs CRISPR Therapeutics AG now and the warning signs.
Free to see. No signup.
Keep reading
More on CRISPR Therapeutics AG and the records around it.
CRISPR Therapeutics AG elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- ARK Investment Management LLC also filed stake reports on 20 other companies: 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026), 908 Devices Inc. (Aug 2026)
- ORBIS INVESTMENT MANAGEMENT LTD also filed stake reports on 23 other companies: National CineMedia, Inc. (Sep 2026), BBB FOODS INC (Aug 2026), Burford Capital Ltd (Aug 2026)
- Capital International Investors also filed stake reports on 95 other companies: Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026), BBB Foods Inc. (Aug 2026)
Watch CRISPR Therapeutics AG
Get an email when CRISPR Therapeutics AG files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CRISPR Therapeutics AG?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CRISPR Therapeutics AG: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CRISPR Therapeutics AG covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on CRISPR Therapeutics AG: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at CRISPR Therapeutics AG, with the record behind each one.
Find candidates like senior executive at CRISPR Therapeutics AGEvery change, in the filing's words
Reported
a) Appointment of New Chief Financial Officer Appointment of Andrew J. Silver as Chief Financial Officer On October 19, 2026, CRISPR Therapeutics AG (the "Company") announced the promotion of Andrew J. Silver, currently the Company's SVP, Finance, to be the Company's Chief Financial Officer effective immediately.
Tools for this story
Each opens in a new tab, filled in for CRISPR Therapeutics AG. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.